Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to address the longtime challenge of bringing their treatments to patients by ...
Roche has added to its flotilla of RNA alliances, handing Ascidian Therapeutics $42 million upfront to use an alternative to gene editing to treat neurological diseases. The agreement includes up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback